Country intelligence
Deals, market moves, science and policy across the platform tagged to Czech Republic.
One of Europe's more liberal markets, easing access further and building an export sector.
Market sizing, forecasts, pricing and patient data are available to Prohibition Partners subscribers. View on Prohibition Partners →
Legalised in 2013 under Act 50/2013, with conditions and handling rules set by Ministry of Health decrees. A January 2022 amendment removed the cultivation tender and allowed licensing, fuelling new suppliers, an export market and lower prices.
Since April 2025 GPs as well as specialists can prescribe for chronic pain; other indications require a relevant specialist. Approved uses include intractable pain, MS/spinal injury, chemotherapy-related symptoms and Tourette's.
Public insurers cover the bulk of costs up to a monthly limit, with patients paying out of pocket above it.
The market is flower-dominated with a growing extract share; most registered products are imported, largely from Canada, while new domestic EU-GMP cultivators expand their portfolios.
The country recorded its first exports to Germany in 2024 and ramped volumes rapidly, with several domestic producers entering export markets.
Nothing tagged to Czech Republic yet. Tag deals, studies or articles with this country to see them here and on the map.
